The Perils of Ignoring Negative Data

Today, Eleven Biotherapeutics (NASDAQ:$EBIO) announced the failure of its Phase 3 trial of an IL1 receptor antagonist in dry eye.   The company indicated they saw no way forward for the product candidate in this indication, which with a little translation, indicates a comprehensive failure of the study (rather than a near-miss on the primary end-point, for example). Unsurprisingly, the company lost most (-69% as at 4.20pm EDT) of its value as a result.

from Forbes – Business http://ift.tt/1QY6ZDe
via Abogado Aly Business Consulting

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s